drugset / Trial / NCT05162872
Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
this study is aimed to evaluate the efficacy and safety of the combination of Niraparib and Sintilimab in the treatment of recurrent/metastatic nasopharyngeal carcinoma
Timeline
- Start
- 2021-08-05
- Primary completion
- 2023-06-30
- Completion
- 2023-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 200 mg | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |